Early Screening for Multiple Myeloma Based on Liquid Biopsy cfDNA Fragmentomics

Early Screening for Multiple Myeloma Based on Liquid Biopsy cfDNA Fragmentomics

Study on Early Screening of Myeloma Based on Liquid Biopsy cfDNA Fragmentomics Technology. This study aims to construct and validate a set of machine learning models for the early screening of myeloma tailored to the Chinese population, based on plasma cfDNA fragmentomics features, to effectively distinguish myeloma patients from healthy individuals.

Inclusion Criteria:

• Age over 40 years.
• Diagnosed with MM, SMM, or MGUS through standard diagnostic procedures.
• Voluntarily participating and signed written informed consent.

Exclusion Criteria:

• Pregnant or lactating women.
• Prior cancer diagnosis within the past 5 years, or history of any form of systemic cancer therapy (including chemotherapy, targeted therapy, immunotherapy, etc.).
• History of organ transplantation, or allogeneic bone marrow or stem cell transplantation.
• History of blood transfusion within 7 days prior to blood collection.
• Poor compliance or potential interference with signing informed consent as judged by the investigator, or any other conditions rendering the subject unsuitable for the study.